Papillary thyroid microcarcinoma: retrospective analysis of 160 cases

Abstract

Aims: This study aims to retrospectively evaluate the clinical and histopathological features of 160 cases diagnosed with papillary thyroid microcarcinoma (PTMC) and to determine the factors affecting the behavior of the tumor. Although PTMC generally has a benign course, it is aimed to contribute to clinical management strategies by defining the aggressive features it exhibits in some cases. Methods: 160 cases diagnosed with PTMC at the Department of Pathology of Tokat Gaziosmanpaşa University Faculty of Medicine between January 2010 and December 2023 were included in the study. Pathology reports of the cases were retrospectively examined; age, gender, number of tumor foci, location, tumor diameter, histological type, capsule invasion, lymphovascular invasion, extrathyroidal spread, presence of lymph node and distant metastasis, and accompanying thyroid diseases were recorded. In addition, preoperative thyroid fine needle aspiration biopsy results and surgical methods were analyzed. Statistical analyses were performed using SPSS 22.0 program. Results: The mean age of the 160 cases was 48.4 years, and 78.1% were female. 65.6% of the tumors were unifocal, 34.4% were multifocal, and 20% were bilateral. The mean tumor diameter was 5.2 mm, and 59.4% of the cases had a diameter of 5 mm or smaller. Among the histological types, 51.3% were follicular, 43.7% were classical variants. Extrathyroidal spread was observed in 5.6% of the cases, lymphovascular invasion in 3.75%, and lymph node metastasis in 2.5%. The most common diagnosis in 28.4% of the cases in which thyroid FNAB was performed was “atypia of undetermined significance”. The most common accompanying thyroid diseases were multinodular goiter in 46.3% and Hashimoto thyroiditis in 33.8%. Conclusion: Although PTMC generally has a benign course, it can exhibit aggressive behavior such as multifocality, extrathyroidal spread, and lymph node metastasis in some cases. Therefore, an individualized treatment approach should be adopted by considering not only the tumor diameter but also all histopathological features. Due to the heterogeneous nature of PTMC, it reveals the need for prospective and multicenter advanced studies.

Keywords

• Papillary thyroid carcinoma
• microcarcinoma
• thyroid neoplasm

Papiller tiroid mikrokarsinoma: 160 olgunun retrospektif analizi

Abstract

Amaç: Bu çalışma, papiller tiroid mikrokarsinomu (PTMC) tanısı almış 160 olgunun klinik ve histopatolojik özelliklerini retrospektif olarak değerlendirerek, tümörün davranışını etkileyen faktörleri belirlemeyi amaçlamaktadır. PTMC'nin genellikle iyi seyirli olmasına rağmen, bazı olgularda gösterdiği agresif özelliklerin tanımlanması ile klinik yönetim stratejilerine katkı sağlanması hedeflenmiştir. Metodlar: Ocak 2010-Aralık 2023 tarihleri arasında Tokat Gaziosmanpaşa Üniversitesi Tıp Fakültesi Patoloji Anabilim Dalı'nda PTMC tanısı konmuş 160 olgu çalışmaya dahil edilmiştir. Olguların patoloji raporları retrospektif olarak incelenmiş; yaş, cinsiyet, tümör odak sayısı, yerleşim yeri, tümör çapı, histolojik tip, kapsül invazyonu, lenfovasküler invazyon, ekstratiroidal yayılım, lenf nodu ve uzak metastaz varlığı, eşlik eden tiroid hastalıkları gibi parametreler kaydedilmiştir. Ayrıca cerrahi öncesi tiroid ince iğne aspirasyon biyopsisi (İİAB) sonuçları ve cerrahi yöntemler analiz edilmiştir. İstatistiksel analizler SPSS 22.0 programı ile yapılmıştır. Bulgular: 160 olgunun ortalama yaşı 48,4 olup, %78,1’i kadındı. Tümörlerin %65,6’sı tek odaklı, %34,4’ü multifokal, %20’si bilateral yerleşimliydi. Ortalama tümör çapı 5,2 mm idi ve olguların %59,4’ünde çap 5 mm veya daha küçüktü. Histolojik tipler içinde %51,3’ü folliküler, %43,7’si klasik varyanttı. %5,6 olguda ekstratiroidal yayılım, %3,75’inde lenfovasküler invazyon ve %2,5’inde lenf nodu metastazı gözlendi. Tiroid İİAB yapılan olguların %28,4’ünde en sık tanı “önemi belirsiz atipi” idi. En sık eşlik eden tiroid hastalıkları ise %46,3 ile multinodüler guatr ve %33,8 ile Hashimoto tiroiditiydi. Sonuç: PTMC genellikle iyi seyirli olmakla birlikte, bazı olgularda multifokalite, ekstratiroidal yayılım ve lenf nodu metastazı gibi agresif davranış gösterebilmektedir. Bu nedenle yalnızca tümör çapına göre değil, tüm histopatolojik özellikler dikkate alınarak bireyselleştirilmiş bir tedavi yaklaşımı benimsenmelidir. PTMC’nin heterojen doğası nedeniyle, prospektif ve çok merkezli ileri çalışmalara olan ihtiyacı ortaya koymaktadır.

Keywords

• Papiller Tiroid Karsinoma
• Mikrokarsinoma
• Tiroid Neoplazm

References

1. Slijepcevic N, Zivaljevic V, Marinkovic J, Sipetic S, Diklic A, Paunovic I. Retrospective evaluation of the incidental finding of 403 papillary thyroid microcarcinomas in 2466 patients undergoing thyroid surgery for presumed benign thyroid disease. BMC Cancer. 2015;15:1-8. doi:10. 1186/s12885-015-1352-4
2. Neuhold N, Schultheis A, Hermann M, Krotla G, Koperek O, Birner P. Incidental papillary microcarcinoma of the thyroid-further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol. 2011;18(12):3430-3436. doi:10.1245/s10434-011-1663-x
3. Singhavi HR, Mair M, Qayyumi B, Singh A, Chaturvedi P. Thyroid papillary microcarcinoma-carcinoma with clinically benign behaviour. J Head Neck Physic Surg. 2023;11(2):95-101. doi:10.4103/jhnps.jhnps_44_ 23
4. Davies T, Royce W, Crosbie R, Townsley R. Investigation and management of papillary thyroid microcarcinoma-a Scottish regional case series and literature review. Scott Med J. 2021;66(4):191-196. doi:10.1177/00369330211032352
5. WHO Classification of Tumours Editorial Board: Endocrine and Neuroendocrine tumours, vol.8. 5th edn. 2022 (International Agency for Research on Cancer, Lyon, France).
6. Basolo F, Macerola E, Poma AM, Torregrossa L. The 5th edition of WHO classification of tumors of endocrine organs: changes in the diagnosis of follicular-derived thyroid carcinoma. Endocrine. 2023;80(3):470-476. doi:10.1007/s12020-023-03336-4
7. Kovacevic B, Vucevic D, Cerovic S, Eloy C. Peripheral versus intraparenchymal papillary thyroid microcarcinoma: different morphologies and PD-L1 expression. Head Neck Pathol. 2022;16(1):200-212. doi:10.1007/s12105-021-01337-1
8. Džepina D, Bedeković V, Čupić H, Krušlin B. Papillary thyroid microcarcinoma: clinical and pathological study of 321 cases. Coll Antropol. 2012;36(2):39-45.

9. Erol V, Makay Ö, Ertan Y, et al. Tiroid papiller mikrokarsinomlarında multisentrisite. Ulusal Cer Derg. 2010;26:199-202. doi:10.5097/1300-0705.UCD.634-10.02
10. Shi L, Chen JH, Wang ST, Xiong YQ, Huang T. Treatment for papillary thyroid microcarcinoma. Contemp Oncol (Pozn). 2013;17(1):20-23. doi: 10.5114/wo.2013.33769
11. Seyrek NC, Baser H, Topaloglu O, et al. Ultrasonographical, clinical and histopathological features of 1264 nodules with papillary thyroid carcinoma and microcarcinoma based on tumor size. Arch Endocrinol Metab. 2020;64(5):533-541. doi:10.20945/2359-3997000000286
12. Şahin Y, Durak MG. Tiroid papiller mikrokarsinomun moleküler özellikleri. Dokuz Eylül Üniv Tıp Fak Derg. 2024;38(3):281-292. doi:10. 18614/deutip.1503245
13. Carnazza M, Quaranto D, DeSouza N et al. The current understanding of the molecular pathogenesis of papillary thyroid cancer. Int J Mol Sci. 2025;26(10):4646. doi:10.3390/ijms26104646
14. Xiang T, Yan W, Zhou L. Retrospective analysis of prognostic factors in patients of papillary thyroid microcarcinoma. Oncotarget. 2018;9(85): 35553-35558 doi:10.18632/oncotarget.26248
15. Shen Y, Pu W, Zhou H, et al. Risk factors for central lymph node metastasis in papillary thyroid microcarcinoma-a retrospective study of 1433 cases from a single center. Pol J Pathol. 2022;73(3):191-197. doi:10. 5114/pjp.2022.124486
16. Yan L, Blanco J, Reddy V, Al-Khudari S, Tajudeen B, Gattuso P. Clinicopathological features of papillary thyroid microcarcinoma with a diameter less than or equal to 5 mm. Am J Otolaryngol. 2019;40(4):560-563. doi:10.1016/j.amjoto.2019.05.003
17. de Ywata Carvalho A, Kohler HF, Gomes CC, Vartanian JG, Kowalski LP. Predictive factors of recurrence of papillary thyroid microcarcinomas: analysis of 2,538 patients. Int Arch Otorhinolaryngol. 2021;25(04):585-593. doi:10.1055/s-0040-1722253
18. Didehban S, Abdollahi A, Meysamie A. Evaluation of etiology, clinical manifestations, diagnosis, follow-up, histopathology and prognosis factors in papillary thyroid microcarcinoma: a systematic review and meta-analysis. Iran J Pathol. 2023;18(4):380-391. doi:10.30699/IJP.2023. 2005196.3134
19. Lee HS, Park HS, Kim SW, et al. Clinical characteristics of papillary thyroid microcarcinoma less than or equal to 5 mm on ultrasonography. Eur Arch Otorhinolaryngol. 2013;270(11):2969-2974. doi:10.1007/s00405-013-2634-6
20. Roti E, Rossi R, Trasforini G et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metabol. 2006;91(6):2171-2178. doi:10. 1210/jc.2005-2372
21. Liu J, Singh B, Tallini G, et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer. 2006;107(6):1255-1264. doi:10.1002/cncr.22138
22. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871): 1058-1069. doi:10.1016/S0140-6736(13)60109-9
23. Ito Y, Miyauchi A, Kihara M, Kobayashi K, Miya A. Prognostic values of clinical lymph node metastasis and macroscopic extrathyroid extension in papillary thyroid carcinoma. Endocr J. 2014;61(8):745-750. doi:10. 1507/endocrj.ej14-0138
24. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH. Papillary microcarcinoma of the thyroid-prognostic significance of lymph node metastasis and multifocality. Cancer. 2003;98(1):31-40. doi:10.1002/cncr.11442
25. Arican CD, Ozturk T, Sager MS, et al. Incidental papillary microcarcinoma and papillary thyroid carcinoma in multinodular goiter. Anal Cell Pathol (Amst). 2023;2023(1):2768344. doi:10.1155/2023/2768344
26. Medas F, Canu GL, Cappellacci F, et al. Predictive factors of lymph node metastasis in patients with papillary microcarcinoma of the thyroid: retrospective analysis on 293 cases. Front Endocrinol. 2020;11:551. doi:10.3389/fendo.2020.00551
27. Yao S, Zhang H. Papillary thyroid carcinoma with Hashimoto’s thyroiditis: impact and correlation. Front Endocrinol. 2025;16:1512417. doi:10.3389/fendo.2025.1512417
28. Cibas ES, Ali SZ. The 2017 Bethesda system for reporting thyroid cytopathology. Thyroid. 2017;27(11):1341-1346. doi:10.1089/thy.2017.0500
29. Tong L, Kexin M, Ying Z, Fengjing F, Bei W. Clinical treatment status of papillary thyroid microcarcinoma. Advanc Ultrasound Diagnos Ther. 2025;9(1):41-46. doi:10.37015/AUDT.2025.240027